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Acanthamoeba is an opportunistic pathogen in humans, whose infections most commonly manifest as Acanthamoeba keratitis
or, more rarely, granulomatous amoebic encephalitis. Although there are many therapeutic options for the treatment of Acan-
thamoeba, they are generally lengthy and/or have limited efficacy. Therefore, there is a requirement for the identification, valida-
tion, and development of novel therapeutic targets against these pathogens. Recently, RNA interference (RNAi) has been widely
used for these validation purposes and has proven to be a powerful tool for Acanthamoeba therapeutics. Ergosterol is one of the
major sterols in the membrane of Acanthamoeba. 3-Hydroxy-3-methylglutaryl–coenzyme A (HMG-CoA) reductase is an en-
zyme that catalyzes the conversion of HMG-CoA tomevalonate, one of the precursors for the production of cholesterol in hu-
mans and ergosterol in plants, fungi, and protozoa. Statins are compounds which inhibit this enzyme and so are promising as
chemotherapeutics. In order to validate whether this enzyme could be an interesting therapeutic target in Acanthamoeba, small
interfering RNAs (siRNAs) against HMG-CoA were developed and used to evaluate the effects induced by the inhibition of Acan-
thamoebaHMG-CoA. It was found that HMG-CoA is a potential drug target in these pathogenic free-living amoebae, and vari-
ous statins were evaluated in vitro against three clinical strains of Acanthamoeba by using a colorimetric assay, showing impor-
tant activities against the tested strains. We conclude that the targeting of HMG-CoA and Acanthamoeba treatment using statins
is a novel powerful treatment option against Acanthamoeba species in human disease.
Free-living amoebae of the genus Acanthamoeba are ubiquitousprotozoa that pervade the entire environment and include am-
phizoic strains that are pathogenic to humans and other animals
(1). In humans, these protozoa are opportunistic causal agents of
sight-threatening ulcerations of the cornea called Acanthamoeba
keratitis (AK), disseminated infections (mostly cutaneous and na-
sopharyngeal), and fatal granulomatous amoebic encephalitis
(GAE) (1–4).
Present therapeutic measures for Acanthamoeba keratitis rely
on topical applications of antimicrobials, including the combina-
tion of propamidine isothionate and neomycin or chlorhexidine.
Moreover, the length of these treatments makes the process ardu-
ous. Furthermore, as current treatments are poorly effective
against the cyst form of these amoebae, residual infection often
remains even after treatment. No treatment against GAE has been
established, although therapeutic measures have been used with ap-
parent satisfactory effects, even saving the patient’s life or at least
slowing down the progression of the amoebic infection (1–3, 5).
Chlorhexidine and polyhexamethylene biguanide (PHMB) as mono-
therapy agents have been proven not to be sufficient against clinical or
environmental strains of acanthamoebae, hence the importance of
multiple-strain testing of drugs againstAcanthamoeba, as their effec-
tiveness might depend on theAcanthamoeba isolate (6–9). There is a
need to search for and validate new therapeutic targets againstAcan-
thamoeba, focusing mostly on key proteins related to cellular viability
and the pathogenesis of Acanthamoeba.
3-Hydroxy-3-methylglutaryl– coenzyme A (HMG-CoA) re-
ductase is an enzyme involved in the conversion of HMG-CoA to
mevalonate, a precursor of cholesterol in humans and ergosterol
in plants, fungi, and protozoa (10, 11). In Acanthamoeba, ergos-
terol and 7-dehyrostigmasterol have been reported to be the main
sterols of the membrane in both the trophozoite and the cyst
forms (12–15). Therefore, if this enzyme is blocked or inhibited,
defective membrane architecture as well as an increased permea-
bility and leakage of ions from the cell should be expected. How-
ever, the presence of this enzyme in Acanthamoeba has not been
previously demonstrated until the present study.
RNA interference (RNAi) was previously applied to Acan-
thamoeba for the elucidation of key processes in this genus by
using chemically synthesized specific small interfering RNAs
(siRNAs) and was also recently proposed as a possible therapeutic
approach against acanthamoebae, at least in vitro. Therefore, the
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use of siRNAs for Acanthamoeba currently presents a powerful
tool to validate and evaluate suspected drug targets or develop
novel therapeutic approaches. In this work, siRNAs against
HMG-CoA were developed and tested in order to evaluate the
potential use of this enzyme in future therapies. Once vali-
dated, the following step was the search for active compounds
that can inhibit the target. For this purpose, statins were used in
this study.
Statins are a family of lipid-lowering drugs widely used to con-
trol cholesterol levels and to prevent stroke and cardiac failure in
patients at a high risk of coronary artery disease. The mechanism
of action of statins is the inhibition of HMG-CoA reductase by
binding to the active site of this enzyme (16). This process is a
process of competitive inhibition with respect to the substrate.
Moreover, it has been reported that several residues in the catalytic
region of HMG-CoA reductase can participate in substrate catal-
ysis. Especially, the active-site glutamate and aspartate are con-
served in all known HMG-CoA reductases, and the changes in
activity that accompany their mutagenesis support their proposed
roles in catalysis (17).
Different statins have been used against some parasites, such as
Schistosoma mansoni and S. haematobium (18, 19), Leishmania
amazonensis and L. donovani (20, 21),Trypanosoma cruzi (22, 23),
Plasmodium falciparum (24–27), and Toxoplasma gondii (28). St-
atins differ in terms of their chemical structures, pharmacokinetic
profiles, and lipid-modifying efficacies (29). For this reason, the
efficacies of five different statins (simvastatin, pravastatin, lova-
statin, atorvastatin, and fluvastatin) were evaluated against Acan-
thamoeba castellanii Neff and three clinical isolates from contact
lens cases.
MATERIALS AND METHODS
Acanthamoeba strains. Three clinical isolates (CLC-16, genotype T3;
CLC-41.r, genotype T4; and CLC-51, genotype T1) obtained in a previous
study in our laboratory (5) and the Acanthamoeba castellanii type strain
Neff (ATCC 30010, genotype T4) were used in this study.
The four Acanthamoeba strains were axenically grown in PYG me-
dium (0.75% [wt/vol] proteose peptone, 0.75% [wt/vol] yeast extract, and
1.5% [wt/vol] glucose) containing 40 mg/liter gentamicin (Biochrom AG;
Cultek, Granollers, Barcelona, Spain) at room temperature. However,
experiments were carried out at 28°C.
Statins. Five statins were used in this work: simvastatin, which was
kindly provided by Merck Chemical Spain Ltd. (Barcelona, Spain); prav-
astatin and atorvastatin, which were purchased from Sigma-Aldrich
Chemistry Ltd. (Madrid, Spain); and lovastatin and fluvastatin, which
were purchased from Enzo Life Sciences Inc. (Taper Group, Spain).
Design of HMG-CoA reductase PCR. The predicted coding sequence
of Acanthamoeba HMG-CoA (Ac-HMG-CoA) was generated as part of
the ongoing Acanthamoeba Genome Project (accession number
AHJI01000000) being carried out in the laboratory of Brendan Loftus (B.
Loftus, personal communication).
A comparative analysis of this sequence was carried out by using the
available HMG-CoA reductase sequences in the GenBank database using
MEGA5.0 software (30).
Primers were designed by using primer 3 software in order to verify the
validity of these sequences for all the strains to be used in this study (31).
The designed primer pair was Ac-HMG-CoA-F (5=-TGACTCGTGGTCC
TTGTGTTCGT-3=) and Ac-HMG-CoA-R (5=-TGACCAGCAGCAAGA
FIG 1 Amino acid sequences that surround the conserved acidic residues of the catalytic domain of the available sequences of HMG-CoA reductases in the
GenBank database and the Acanthamoeba HMG-CoA reductase. The comparative analysis of the catalytic domains of the HMG-CoA reductases revealed 1
conserved aspartate and 2 conserved glutamate residues (asterisks).
FIG 2 Distribution of Acanthamoeba CLC-51.l cell line trophozoites, cysts, and nonviable cells at 6, 12, 24, and 48 h in the absence (A) and in the presence (B)
of HMG-CoA reductase siRNA. The cell distribution (number of different cell types) at different time points was determined by using microscopy and cell
counting. All experiments were repeated three times. Similar results were obtained with the other strains used in this study.
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GCAGCC-3=). The PCR mixture included 5 pmol each primer, 40 ng of
DNA (from clinical isolates and the type strain), and 0.25 U of Taq poly-
merase (Bioline; Ecogen Biologia Molecular, Spain). The amplification
cycles used were 94°C for 5 min; 94°C for 30 s, 50°C for 15 s, and 72°C for
15 s (for 35 cycles); and 72°C for 7 min.
HMG-CoA reductase silencing. Gene silencing was performed with
the following Stealth RNAi siRNAs specifically designed against HMG-
CoA reductase by using BLOCK-it RNAi designer software (Invitrogen):
ST-siRNA-1 (UGCUUCUACUCAUCGUGGUUGUAAA) and ST-
siRNA-2 (UCUUCAUGUUAAAGGUGCUUCUGAA). X-treme Gene
siRNA transfection reagent (Roche) was used in order to improve the
silencing efficacy without induced cytotoxicity problems (32). The exper-
iment was performed with the four strains mentioned above and was
carried out in triplicate starting with 104 cells/ml and adding 15 g/ml of
the ST-siRNAs to the medium, as previously described (33). The effect
induced by the siRNA treatment was evaluated by using microscopy and
cell counting. After 96 h, the cells were incubated in fresh PYG medium in
order to check cell viability (capacity of amoebae to excyst).
Effects of the transfection reagent and siRNA were checked by carrying
out control experiments with siRNAs which encode green fluorescence
protein (scrambled siRNA), GFP-siRNA-1 (UUUACAACCACGAUGAG
UAGAAGCA) and GFP-siRNA-2 (UUCAGAAGCACCUUUAACAUGA
AGA), as previously described (33).
Activity assays.The anti-Acanthamoeba activities of the assayed drugs
were determined by the alamarBlue assay, as previously described (5, 34,
35). Briefly, Acanthamoeba trophozoites were seeded into a 96-well mi-
crotiter plate with 50 l from a stock solution of 8  104 cells/ml. After
that, 50l of serial dilutions of statins in PYG medium were added to each
well, and finally, alamarBlue assay reagent (Biosource Europe, Nivelles,
Belgium) was placed into each well at an amount equal to 10% of the
medium volume. Test plates containing alamarBlue were then incubated
for 120 h at 28°C with slight agitation.
Subsequently, the plates were analyzed during an interval of time be-
tween 72 and 120 h on a model 680 microplate reader (Bio-Rad, Hercules,
CA), using a test wavelength of 570 nm and a reference wavelength of 630
nm. Percentages of growth inhibition, 50% inhibitory concentrations
(IC50) and 90% inhibitory concentrations (IC90), for each molecule were
calculated by linear regression analysis with 95% confidence limits. All
experiments were performed three times each in duplicate, and the mean
values were also calculated. A paired two-tailed t test was used for analyses
of the data. P values of0.05 were considered significant. The statistical
analysis of the inhibition curves was undertaken by using the Sigma Plot
12.0 software program (Systat Software Inc.).
Cysticidal activity. The effects of statins against cysts were evaluated
by incubating 104 cysts ofA. castellaniiNeff with the previously calculated
IC50s and IC90s of the statins in PYG medium. The numbers of trophozo-
ites, cysts, and nonviable cysts were counted with a Neubauer chamber at
96, 120, 144, and 168 h.
Cell proliferation. In order to study the effects of the tested active
compounds on Acanthamoeba castellanii Neff cell proliferation, a Cell
Proliferation enzyme-linked immunosorbent assay (ELISA) bromode-
oxyuridine (BrdU) (colorimetric) kit was used (Roche), according to the
manufacturer’s recommendations. Briefly, the assay was carried out in
96-well plates with 104 cells/ml per well. The concentrations used were the
FIG 3 Light microscopy (magnification,20) images corresponding to the assay that was carried out with Acanthamoeba castellanii Neff. Similar results were
obtained with the other clinical strains included in this study. (A and C) Controls at 24 h (A) and 48 h (C) are shown as trophozoites. (B and D) Treated cells at
24 h (B) and 48 h (D) are shown as rounded and lysed cells (arrow).
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IC50s and IC90s, and the obtained results were analyzed at 24, 48, and 72 h.
The obtained results were compared by one-way analysis of variance
(ANOVA) and by multiple post hoc analysis and Tukey’s test using Sigma
Plot 12.0 software (Systat Software).
Cytotoxicity test. The cytotoxicity produced by active compounds
was evaluated against the following cell lines from mammals: murine
macrophages (ATCC TIB-67) and HeLa cells (ATCC CCL-2). A cytotox-
icity detection kit (lactate dehydrogenase; Roche Applied Science) was
used according to the manufacturer’s recommendations. Results were
classified based on previously established parameters: the active principles
with percentages of cytotoxicity of between 0 and 10% were not cytotoxic,
values between 10 and 25% correspond to low cytotoxicity, values be-
tween 25 and 40% are equivalent to moderate cytotoxicity, and values of
at least 40% indicate high cytotoxicity (32).
RESULTS
HMG-CoA reductase silencing. The presence of the sequence of
HMG-CoA reductase in Acanthamoeba was verified in all tested
strains. Furthermore, the comparative analysis revealed that the
catalytic region of this enzyme is conserved in Acanthamoeba
(Fig. 1). After that, siRNA-based gene silencing assays were thus
carried out by targeting this enzyme.
The results obtained were similar for all the tested strains.
Numbers of untreated control trophozoites increased exponen-
tially during the entire experiment (Fig. 2A). Unlike the control,
the number of cells treated with siRNA decreased up to 48 h post-
treatment. At this time, the cells were no longer viable (Fig. 2B),
and cells undergoing lysis were observed (Fig. 3).
In response to treatment with siRNA, some cells began the
process of encystation by forming precysts. However, these
precysts were not viable, as they were unable to revert to tro-
phozoites when transferred into fresh PYG medium, even after
168 h.
Activity assays. The amoebicidal activities of the tested statins
are summarized in Table 1. We observed that the most active
statins are simvastatin, fluvastatin, and atorvastatin. With the A.
castellanii type strain Neff, pravastatin was the least active statin
and was no longer tested. However, lovastatin also exhibited a low
level of activity against the clinical strains. Effective drug concen-
trations higher than 100 M were not considered useful.
In order to check the cysticidal activities of statins against A.
castellanii Neff, lovastatin, simvastatin, fluvastatin, and atorvasta-
tin (the most active statins) (Table 1) at the previously calculated
IC90 values were incubated in wells with 10
4 cells/ml.
Excystation did not occur except when the IC90 of lovastatin
was used (less active molecule from the used ones) (Fig. 4A); how-
ever, if we compared it with the control, the amount of cells was
small.
FIG 4 Effects of statins against cysts were evaluated by incubating 104 cysts ofA. castellaniiNeff with the previously calculated IC50 and IC90 values of the selected
statins in PYG medium, and cells were counted with a Neubauer chamber at between 96 and 168 h. (A) Number of cysts that reverted to trophozoites in PYG
medium after incubation with statins. (B) Number of nonviable cysts when cysts were incubated with the previously calculated IC90s of statins in PYG medium.
TABLE 1 IC50 and IC90 values of statins tested against different strains of Acanthamoeba at 96 h
Statin
Mean concn (M) at 96 h SDa
AcNeff CLC-16 CLC-41.r CLC-51.l
IC50 IC90 IC50 IC90 IC50 IC90 IC50 IC90
Atorvastatin 15.12 2.19 41.09 0.01 33.34 2.64 78.66 5.85 13.70 0.81 26.10 1.18 26.63 1.20 49.76 1.81
Fluvastatin 9.19 0.98 20.70 2.15 54.64 2.69 105.40 5.34 24.29 0.97 55.17 2.91 16.50 1.03 32.86 5.18
Lovastatin 17.14 1.85 NA NA NA 46.65 4.50 NA NA NA
Pravastatin 58.75 11.01 NA NA NA NA NA NA NA
Simvastatin 10.24 1.09 21.37 1.51 31.44 2.06 63.55 4.15 14.60 0.59 29.85 1.16 39.73 4.34 84.16 8.23
a NA, no activity.
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We observed that the number of cysts decreased during the
time period due to reversion to trophozoites (especially when lo-
vastatin was used), and others may have been nonviable. Nonvia-
ble cysts were observed with all statins; however, when fluvastatin
was used, all initial cysts became nonviable (Fig. 4B).
The effect of each of the statins on Acanthamoeba castellanii
Neff cell proliferation from 24 to 72 h was checked. It was noted
that all active principles decreased the cell proliferation in a dose-
dependent manner (Fig. 5). Furthermore, significant differences
between the IC50s and IC90s were observed, with the exception of
fluvastatin (Fig. 5B), which may serve to establish the IC50 as the
concentration sufficient to eliminate the cell population.
Cytotoxicity assays. The results showed that the atorvastatin
IC50 and IC90, the fluvastatin IC50 and IC90, and the simvastatin
IC50 presented low cytotoxicity (the IC50 of simvastatin was not
cytotoxic to macrophages, but it was cytotoxic to HeLa cells). The
simvastatin IC90 produced high cytotoxicity. In summary, all
IC50s showed null or low cytotoxicity. In the case of the IC90,
simvastatin showed only high cytotoxicity (Fig. 6).
DISCUSSION
The enzyme 3-hydroxy-3-methylglutaryl– coenzyme A (HMG-
CoA) reductase is widely expressed in vertebrates, and it has been
identified in protistan parasites such as Trypanosoma and Leish-
FIG 5 Observed cell proliferation after incubation of Acanthamoeba castellanii strain Neff with the selected statins compared to the control using the previously
obtained IC50 and IC90 values. Results were analyzed at 24, 48, and 72 h. Significant differences between the IC50s and IC90s were observed for atorvastatin (A)
and simvastatin (C), with the exception of fluvastatin (B).
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mania (36). The amino acids involved in the active site of HMG-
CoA reductases have been identified for a number of species, and
these have been found to be conserved (17). In this study, we have
identified the gene encoding Acanthamoeba HMG-CoA reduc-
tase, and we have found that these conserved amino acids are also
present (Fig. 1), leading us to suspect that statins may also inhibit
the amoebal enzyme.
We have demonstrated that the enzyme is a potential target for
the development of treatments against Acanthamoeba spp. by re-
ducing its expression through siRNA. However, although siRNA
has been proposed as a therapy (32, 37), it would be a very expen-
sive and controversial treatment. Instead, we have investigated the
effects of inhibiting HMG-CoA reductase activity in Acantham-
oeba with a range of statins.
Statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and
simvastatin) have been widely used as a treatment for hypercho-
lesterolemia, as they inhibit HMG-CoA reductase, an enzyme that
converts HMG-CoA to mevalonate, which is a precursor of cho-
lesterol in vertebrates and ergosterol in fungi and some protozoa
(36). In Acanthamoeba, ergosterol and 7-dehyrostigmasterol are
major sterol membrane components of both the nonpathogenic
species A. castellanii and the pathogenic A. culbertsoni strain A-1
(12, 13, 15). We found that statins are amoebicidal and cysticidal,
possibly because both stages of the amoeba contain and require
ergosterol (15).
Statins are molecules that differ in their chemical structures,
pharmacokinetics, and efficacies. From this point of view, the st-
atins most effective at lowering cholesterol levels in humans are
rosuvastatin, atorvastatin, simvastatin, and pravastatin (29). It
was reported previously that statins are also effective in the treat-
ment of certain cancers, but the exact mechanism of this antipro-
liferative activity remains unclear (38). The hydrophobicity of the
molecules correlates with the anticancer effect of lipophilic statins
such as atorvastatin, mevastatin, simvastatin, and rosuvastatin,
reducing the risk of progression and prostate cancer mortality
(39).
Some statins (atorvastatin, fluvastatin, lovastatin, pravastatin,
and simvastatin) were previously tested against various parasitic
protozoa, such as S. haematobium (19), S. mansoni (18), P. falcip-
arum (24–27), T. gondii (24, 28), T. cruzi (23), and Leishmania
amazonensis and L. donovani (20, 21). Although we have shown
here that various statins are effective against Acanthamoeba in in
vitro studies, this does not guarantee that it will be effective in vivo.
For example, although simvastatin is effective against Plasmodium
(24), the drug by itself showed no inhibition of the growth of the
parasite in vivo (40).
If the in vitro activity of these molecules proves effective with-
out producing cytotoxicity, they can be considered molecules for
future treatments. In this sense, atorvastatin and fluvastatin seem
suitable for this purpose. However, because of the moderate to
high levels of cytotoxicity seen with simvastatin at the IC90, the use
of the drug may be not be suitable as a treatment.
The range of concentrations of this class of molecules with
activity against trophozoites is between 9 and 58 M. The calcu-
lated concentrations are lower that the dosage of statins (even
when bioavailability is taken into account) used for the treatment
of hypercholesterolemia (Consejo General de Colegios Oficiales
de Farmaceuticos, Spain). It is therefore possible that the present
regime for controlling cholesterol levels in patients will be suitable
as a treatment for systemic infections byAcanthamoeba.This drug
regime may also be effective even for the treatment of GAE cases,
as statins are able to penetrate the blood-brain barrier (29, 41).
However, because of the very serious nature of GAE, higher statin
levels may be used, and any side effects must be accepted and
lessened to some extent and compensated for by dietary uptake
(23). In the case of Acanthamoeba keratitis, the application of
statins in the form of eye drops may be a better way to deliver
statins at high doses when it is required. Additionally, further ex-
periments should be carried out in order to confirm whether st-
atins act differently at different temperatures, since this seems not
to have been investigated.
To the best of our knowledge, this is the first time that statins have
been tested againstAcanthamoeba, and our results show the promise
of statins as a novel therapy against this facultative pathogen.
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